Novartis AG Common Stock (NY:NVS)

141.00 -0.05 (-0.04%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

3 Dividend Stocks to Buy in 2026 and Hold Forever ↗

January 11, 2026

All three offer much more than a regular payout.

Via The Motley Fool

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Via MarketMinute

Topics Intellectual Property

BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism

January 09, 2026

In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...

Via MarketMinute

Topics Intellectual Property

Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals ↗

January 01, 2026

Via Chartmill

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

Trade War 2.0: Markets Braced as Trump’s 2026 Tariff ‘Salvos’ Reshape the Global Supply Chain

January 08, 2026

As of January 8, 2026, the global financial landscape is undergoing a seismic shift driven by President Trump’s latest round of "tariff salvos." These aggressive trade policies, which dominated the...

Via MarketMinute

Topics Economy Government World Trade

New Investors: 3 Stocks to Build Your Portfolio Around in 2026 ↗

January 08, 2026

These stocks listed here have excellent valuations, promising growth prospects, and they pay dividends.

Via The Motley Fool

The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets

January 07, 2026

The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Why Salesforce Rose 16% in December ↗

January 07, 2026

The cloud stock gained after a better-than-expected earnings report.

Via The Motley Fool

Topics Artificial Intelligence

Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗

January 07, 2026

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Via Stocktwits

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

Via Stocktwits

Topics Government

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Topics Economy Intellectual Property Stocks

The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis

January 01, 2026

In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...

Via TokenRing AI

Topics Artificial Intelligence

The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery

January 01, 2026

The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model...

Via TokenRing AI

Topics Artificial Intelligence

Decoding Life’s Blueprint: How AlphaFold 3 is Redefining the Frontier of Medicine

December 31, 2025

The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI...

Via TokenRing AI

Topics Artificial Intelligence Bonds

Invest Outside the U.S. With These Top International ETFs ↗

December 31, 2025

Compare how fund size, holdings, and portfolio breadth set VEA and SPDW ETFs apart for diversified investors.

Via The Motley Fool

Topics ETFs

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗

December 31, 2025

Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.

Via Stocktwits

Topics Economy Government

The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier

December 30, 2025

As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the...

Via TokenRing AI

Topics Artificial Intelligence

AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era

December 29, 2025

In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides...

Via TokenRing AI

Topics Artificial Intelligence Climate Change

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ↗

December 29, 2025

Novartis (NVS) presents a classic value investing case: a financially strong pharmaceutical leader trading at a discount to peers, with high profitability and a solid dividend.

Via Chartmill

The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine

December 25, 2025

In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was...

Via TokenRing AI

Topics Artificial Intelligence Initial Public Offering

Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗

December 23, 2025

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.

Via The Motley Fool

Topics Stocks

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

2 Top Stocks to Buy and Hold for the Long Term ↗

December 22, 2025

Both have crushed the market this year.

Via The Motley Fool

Topics Intellectual Property

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗

December 19, 2025

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

Via Investor's Business Daily

Topics Government Stocks

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Via Stocktwits

Topics Economy Government

White House Readies Drug Price Deals With AbbVie, Novartis, Roche ↗

December 18, 2025

AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.